A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an...

Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizon™ Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted...

Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine...

Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA®...

Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes...

With women's health, obstetric and neonatal nurses taking on ever-greater responsibilities, there's no better time than AWHONN's 2018 annual convention, from today through June 27 in Tampa, to see...

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively;...

ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product...